HRP20211997T1 - Novi supstituirani nukleozidni analozi 6-6 bicikličkog aromatskog prstena za upotrebu kao inhibitori prmt5 - Google Patents
Novi supstituirani nukleozidni analozi 6-6 bicikličkog aromatskog prstena za upotrebu kao inhibitori prmt5 Download PDFInfo
- Publication number
- HRP20211997T1 HRP20211997T1 HRP20211997TT HRP20211997T HRP20211997T1 HR P20211997 T1 HRP20211997 T1 HR P20211997T1 HR P20211997T T HRP20211997T T HR P20211997TT HR P20211997 T HRP20211997 T HR P20211997T HR P20211997 T1 HRP20211997 T1 HR P20211997T1
- Authority
- HR
- Croatia
- Prior art keywords
- 4alkyl
- halo
- group
- hydrogen
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209941P | 2015-08-26 | 2015-08-26 | |
| EP15184011 | 2015-09-07 | ||
| US201662306233P | 2016-03-10 | 2016-03-10 | |
| PCT/EP2016/070097 WO2017032840A1 (en) | 2015-08-26 | 2016-08-25 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
| EP16757233.8A EP3341368B1 (en) | 2015-08-26 | 2016-08-25 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211997T1 true HRP20211997T1 (hr) | 2022-04-01 |
Family
ID=54065259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211997TT HRP20211997T1 (hr) | 2015-08-26 | 2016-08-25 | Novi supstituirani nukleozidni analozi 6-6 bicikličkog aromatskog prstena za upotrebu kao inhibitori prmt5 |
Country Status (35)
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| US10898504B2 (en) * | 2016-03-10 | 2021-01-26 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| LT3512857T (lt) | 2016-09-14 | 2021-04-12 | Janssen Pharmaceutica Nv | Menin-mll sąveikos spirobicikliniai inhibitoriai |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| JP7101171B2 (ja) | 2016-10-03 | 2022-07-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 |
| BR112019012106A2 (pt) | 2016-12-15 | 2019-10-29 | Janssen Pharmaceutica Nv | inibidores de azepano de interação menin-mill |
| GB201700526D0 (en) * | 2017-01-12 | 2017-03-01 | Univ Of Hull | Therapeutic use |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| US11279970B2 (en) | 2017-02-27 | 2022-03-22 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor |
| PL3665179T3 (pl) | 2017-08-09 | 2021-11-29 | Prelude Therapeutics, Incorporated | Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5) |
| CA3079545A1 (en) * | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2020243178A1 (en) * | 2019-05-30 | 2020-12-03 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
| CN111741964A (zh) * | 2017-12-05 | 2020-10-02 | 安杰斯制药公司 | 作为prmt5抑制剂的杂环化合物 |
| AU2018379456B2 (en) | 2017-12-08 | 2022-11-24 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
| PE20211444A1 (es) * | 2017-12-13 | 2021-08-05 | Lupin Ltd | Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| CN111971288B (zh) * | 2018-03-14 | 2023-12-01 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US20210309687A1 (en) * | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020132603A2 (en) * | 2018-12-21 | 2020-06-25 | Memorial Sloan-Kettering Cancer Center | Salicyl-adenosinemonosulfamate analogs and uses thereof |
| CN109400545B (zh) * | 2018-12-24 | 2022-03-25 | 济南大学 | 一种精氨酸甲基转移酶5抑制剂及其应用 |
| CN109369507A (zh) * | 2018-12-26 | 2019-02-22 | 重庆市碚圣医药科技股份有限公司 | 一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法 |
| CN113811539A (zh) * | 2019-02-13 | 2021-12-17 | 普莱鲁德疗法有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂 |
| US20220160747A1 (en) * | 2019-03-20 | 2022-05-26 | Korea Research Institute Of Chemical Technology | Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient |
| BR112021019125A2 (pt) * | 2019-03-25 | 2021-11-30 | 1200 Pharma Llc | Inibidores de prmt5 e usos dos mesmos |
| EP3947388A4 (en) | 2019-04-02 | 2022-12-21 | Aligos Therapeutics, Inc. | PRMT5 TARGETING COMPOUNDS |
| JP2022526604A (ja) * | 2019-04-05 | 2022-05-25 | プレリュード・セラピューティクス・インコーポレイテッド | タンパク質アルギニンメチルトランスフェラーゼ５の選択的阻害剤 |
| EP3952874A4 (en) * | 2019-04-05 | 2022-12-28 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| DK3980417T3 (en) * | 2019-06-10 | 2023-12-18 | Lupin Ltd | PRMT5-Inhibitorer |
| JP7598338B2 (ja) | 2019-06-12 | 2024-12-11 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規なスピロ二環式中間体 |
| MX2022003340A (es) * | 2019-09-18 | 2022-06-14 | Prelude Therapeutics Inc | Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5). |
| CN115298179A (zh) * | 2019-10-21 | 2022-11-04 | 埃克森特治疗公司 | Mettl3调节剂 |
| PH12022550909A1 (en) * | 2019-10-22 | 2023-11-20 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| JP7664248B2 (ja) * | 2019-12-03 | 2025-04-17 | ルピン・リミテッド | Ｐｒｍｔ５阻害剤としての置換ヌクレオシドアナログ |
| WO2021126729A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) * | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111233869B (zh) * | 2020-03-12 | 2022-09-16 | 杭州新博思生物医药有限公司 | 用于制备瑞德西韦关键中间体的新化合物及其制备方法 |
| WO2021202480A1 (en) * | 2020-04-01 | 2021-10-07 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| WO2022074391A1 (en) * | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
| CN112645875A (zh) * | 2020-12-09 | 2021-04-13 | 深圳海王医药科技研究院有限公司 | 一种盐酸丙卡特罗杂质的制备方法 |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| WO2023001133A1 (zh) * | 2021-07-20 | 2023-01-26 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| CN115703796A (zh) * | 2021-08-09 | 2023-02-17 | 苏州恩泰新材料科技有限公司 | 一种瑞德西韦重要中间体制备方法 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
| CN116003339B (zh) * | 2022-12-01 | 2024-06-28 | 南京师范大学 | 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| KR101032005B1 (ko) | 2002-02-19 | 2011-05-02 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제 |
| US20040043959A1 (en) * | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| TWI265376B (en) * | 2002-03-20 | 2006-11-01 | Sumitomo Chemical Co | Positive resist composition |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| EP1645561A1 (en) | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
| AU2004311702A1 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
| WO2006078752A2 (en) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| WO2010039548A2 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| CA2784596A1 (en) | 2009-12-18 | 2011-06-23 | Joslin Diabetes Center, Inc. | Beta-cell replication promoting compounds and methods of their use |
| EP2646454B1 (en) * | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| JP5906253B2 (ja) | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
| ES2587512T3 (es) | 2011-04-04 | 2016-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Derivados de 2'-O-aminooximetil nucleósido para su uso en la síntesis y modificación de nucleósidos, nucleótidos y oligonucleótidos |
| WO2013062943A1 (en) | 2011-10-24 | 2013-05-02 | Glaxosmithkline Intellectual Property Development Limited | New compounds |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| CA2894228C (en) * | 2012-12-21 | 2021-08-17 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9856218B2 (en) | 2013-03-15 | 2018-01-02 | Ohio State Innovation Foundation | Inhibitors of PRMT5 and methods of their use |
| WO2015106025A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN106999479B (zh) | 2014-07-01 | 2021-07-16 | 米伦纽姆医药公司 | 可用作sumo活化酶抑制剂的杂芳基化合物 |
| BR112017017396A2 (pt) | 2015-02-24 | 2018-04-03 | Pfizer | derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos |
| TWI730980B (zh) * | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| PE20181894A1 (es) | 2016-03-10 | 2018-12-11 | Janssen Pharmaceutica Nv | Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5 |
| JP7101171B2 (ja) * | 2016-10-03 | 2022-07-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| US11279970B2 (en) | 2017-02-27 | 2022-03-22 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor |
| AU2018379456B2 (en) | 2017-12-08 | 2022-11-24 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
-
2016
- 2016-08-24 TW TW105126988A patent/TWI730980B/zh active
- 2016-08-24 TW TW110127686A patent/TWI791251B/zh active
- 2016-08-24 TW TW112102610A patent/TWI870767B/zh active
- 2016-08-25 SG SG10202003775VA patent/SG10202003775VA/en unknown
- 2016-08-25 MA MA42678A patent/MA42678B1/fr unknown
- 2016-08-25 EP EP16757233.8A patent/EP3341368B1/en active Active
- 2016-08-25 EA EA201890573A patent/EA201890573A1/ru unknown
- 2016-08-25 LT LTEPPCT/EP2016/070097T patent/LT3341368T/lt unknown
- 2016-08-25 PH PH1/2018/500425A patent/PH12018500425B1/en unknown
- 2016-08-25 KR KR1020187007810A patent/KR102716092B1/ko active Active
- 2016-08-25 MX MX2018002326A patent/MX392554B/es unknown
- 2016-08-25 BR BR122023020317-8A patent/BR122023020317A2/pt not_active Application Discontinuation
- 2016-08-25 WO PCT/EP2016/070097 patent/WO2017032840A1/en not_active Ceased
- 2016-08-25 AU AU2016311295A patent/AU2016311295B2/en active Active
- 2016-08-25 SM SM20210725T patent/SMT202100725T1/it unknown
- 2016-08-25 DK DK16757233.8T patent/DK3341368T3/da active
- 2016-08-25 PE PE2018000306A patent/PE20180929A1/es unknown
- 2016-08-25 IL IL311843A patent/IL311843A/en unknown
- 2016-08-25 EP EP23162887.6A patent/EP4219496A1/en active Pending
- 2016-08-25 JP JP2018510334A patent/JP6917978B2/ja active Active
- 2016-08-25 CA CA2992688A patent/CA2992688A1/en active Pending
- 2016-08-25 PH PH1/2021/552054A patent/PH12021552054A1/en unknown
- 2016-08-25 NZ NZ740528A patent/NZ740528A/en unknown
- 2016-08-25 SI SI201631402T patent/SI3341368T1/sl unknown
- 2016-08-25 ES ES16757233T patent/ES2901972T3/es active Active
- 2016-08-25 BR BR112018003595-5A patent/BR112018003595B1/pt active IP Right Grant
- 2016-08-25 US US15/755,475 patent/US10653711B2/en active Active
- 2016-08-25 PT PT167572338T patent/PT3341368T/pt unknown
- 2016-08-25 AR ARP160102600A patent/AR105820A1/es active IP Right Grant
- 2016-08-25 MD MDE20180642T patent/MD3341368T2/ro unknown
- 2016-08-25 CN CN202111120182.2A patent/CN114057815B/zh active Active
- 2016-08-25 EP EP21199207.8A patent/EP3974428A1/en active Pending
- 2016-08-25 MY MYPI2018000274A patent/MY198472A/en unknown
- 2016-08-25 CN CN201680048987.1A patent/CN107922413B/zh active Active
- 2016-08-25 TN TNP/2018/000043A patent/TN2018000043A1/en unknown
- 2016-08-25 PL PL16757233T patent/PL3341368T3/pl unknown
- 2016-08-25 HU HUE16757233A patent/HUE057312T2/hu unknown
- 2016-08-25 PE PE2022000450A patent/PE20221629A1/es unknown
- 2016-08-25 HR HRP20211997TT patent/HRP20211997T1/hr unknown
- 2016-08-25 RS RS20211526A patent/RS62698B1/sr unknown
- 2016-08-25 NZ NZ779003A patent/NZ779003A/en unknown
-
2018
- 2018-02-21 IL IL257664A patent/IL257664B/en active IP Right Grant
- 2018-02-23 MX MX2022005182A patent/MX2022005182A/es unknown
- 2018-02-26 CO CONC2018/0002063A patent/CO2018002063A2/es unknown
- 2018-02-26 CL CL2018000510A patent/CL2018000510A1/es unknown
-
2020
- 2020-03-20 US US16/825,024 patent/US11318157B2/en active Active
-
2021
- 2021-01-20 AU AU2021200345A patent/AU2021200345B2/en active Active
- 2021-04-21 IL IL282537A patent/IL282537A/en unknown
- 2021-07-20 JP JP2021120042A patent/JP7720732B2/ja active Active
-
2022
- 2022-01-04 CY CY20221100008T patent/CY1125359T1/el unknown
- 2022-03-09 US US17/690,587 patent/US11883367B2/en active Active
- 2022-08-11 AU AU2022215260A patent/AU2022215260B2/en active Active
-
2023
- 2023-03-21 US US18/187,463 patent/US20230330127A1/en not_active Abandoned
- 2023-10-27 JP JP2023184701A patent/JP2024012405A/ja not_active Withdrawn
-
2024
- 2024-03-28 AU AU2024202052A patent/AU2024202052A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211997T1 (hr) | Novi supstituirani nukleozidni analozi 6-6 bicikličkog aromatskog prstena za upotrebu kao inhibitori prmt5 | |
| JP2018528946A5 (cg-RX-API-DMAC7.html) | ||
| CL2020001218A1 (es) | Compuestos útiles para inhibir a cdk7. | |
| EP3256149A4 (en) | FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES | |
| HRP20221207T1 (hr) | Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5 | |
| MX2018004008A (es) | Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica. | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| EP3015545A4 (en) | TREHALOSIS AND DEXTRANEOUS SOLUTION FOR THE TRANSPLANTATION OF MAMMALIAN CELLS | |
| CL2016000698A1 (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| MX380711B (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas. | |
| UY33858A (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR092959A1 (es) | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| EP2950718A4 (en) | BLUTSAMMELVORRICHTUNGEN WITH CONTACT PATH -HEMMENDEN ADDITIVES | |
| AR101210A1 (es) | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek | |
| PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
| MA46660A (fr) | Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide | |
| EA201591632A1 (ru) | Цитотоксические и антимитотические соединения и способы их применения | |
| ITUB20159197A1 (it) | Giroscopio microelettromeccanico con reiezione di disturbi e metodo di rilevamento di una velocita' angolare | |
| UY35684A (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
| EP2941833A4 (en) | IMPROVED METHOD FOR CHANNEL QUALITY INFORMATION FEEDBACK | |
| MX2018003993A (es) | Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica. | |
| MX2017000134A (es) | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3 ,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carb oxamida. | |
| EP2949647A4 (en) | DEUTERATED PHENYLAMINOPYRIMIDIN COMPOUND AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| EP3373934A4 (en) | CRYSTALLINE FORM OF A SUBSTITUTED CHINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF |